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BRIEF COMMUNICATION

COVID-19 Infection in Men on Testosterone Replacement Therapy
Amarnath Rambhatla, MD,1 Chandler J. Bronkema, BS,2,3 Nicholas Corsi, BS,2,3 Jacob Keeley, MS,3
Akshay Sood, MD,1,3 Ziad Affas, BS,3 Ali A. Dabaja, MD,1 Craig G. Rogers, MD,1 Stephen A. Liroff, MD,1 and
Firas Abdollah, MD1,3

ABSTRACT

Background: Men who contract coronavirus disease 2019 (COVID-19) appear to have worse clinical outcomes
compared with women which raises the possibility of androgen-dependent effects.
Aim: We sought to determine if testosterone replacement therapy (TRT) is associated with worse clinical
outcomes.
Methods: Through a retrospective chart review, we identiﬁed 32 men diagnosed with COVID-19 and on TRT.
They were propensity score matched to 63 men diagnosed with COVID-19 and not on TRT. Data regarding
comorbidities and endpoints such as hospital admission, intensive care unit admission, ventilator utilization,
thromboembolic events, and death were extracted. Chi-square and Kruskal-Wallis tests examined differences in
categorical and continuous variables, respectively. Logistic regression analysis tested the relationship between
TRT status and the study endpoints.
Results: There were no statistically signiﬁcant differences between the 2 groups, and TRT was not a predictor of
any of the endpoints on multivariate analysis.
Conclusion: These results suggest that TRT is not associated with a worse clinical outcome in men diagnosed
with COVID-19. Rambhatla A, Bronkema CJ, Corsi N, et al. COVID-19 Infection in Men on Testosterone
Replacement Therapy. J Sex Med 2021;18:215e218.
Copyright  2020, International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.
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INTRODUCTION
The outbreak of coronavirus disease 2019 (COVID-19) demonstrates that men have less favorable disease outcomes than
women.1 This suggests the possibility of a testosterone-mediated
disease process for severe disease manifestations, which has led to
the formulation of polar theories. The cytokine theory proposes
that a low testosterone level leads to an increase in proinﬂammatory
cytokines which may facilitate a cytokine storm in men with
COVID-19.2 Conversely, the androgen-driven COVID-19 theory suggests that testosterone, via activation of a transmembrane
protease (TMPRSS2), promotes infection by the severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2).3 An increase
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in venous thromboembolism has also been associated with
COVID-19, particularly in patients who are more severely
affected.4 Testosterone replacement therapy (TRT) is associated
with secondary polycythemia, but it is unclear whether this leads to
an increase in thromboembolic events. However, some authors
have suggested that men should be taken off TRT during this
pandemic.5 Our objective was to determine the impact of TRT on
the clinical outcomes of COVID-19 in men.

MATERIALS AND METHODS
After obtaining institutional review board approval, we performed a retrospective review identifying all men diagnosed with
COVID-19 (ICD-10 code U07.1) who were on TRT from
Henry Ford Health System during March to May 19, 2020.
These men were propensity score matched in a ratio of 1:2 (using
Greedy Nearest Neighbor method, caliper of 0.2) based on age,
race, body mass index (BMI), and ZIP code (proxy for socioeconomic status) to men diagnosed with COVID-19 and not on
TRT (controls). Standardized mean difference was 10% for all
variables after matching. Comorbidity data including smoking
status, hypertension, diabetes, chronic obstructive pulmonary
215
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Table 1. Baseline characteristics and outcomes of 95 men diagnosed with COVID-19, stratiﬁed by testosterone replacement status
All patients (n ¼ 95)

Characteristics and outcomes
Age, years, median (IQR)
Race, n (%)
White
Black
Others
BMI, median (IQR)
Zip code, n (%)
480
481
482
483
492
Comorbidities before COVID-19, n (%)
COPD
Cardiovascular disease
Chronic kidney disease
Diabetes
Hypertension
Immunosuppression
Smoking (current/former)
Hospital admission for COVID-19, n (%)
ICU admission for COVID-19, n (%)
Thromboembolic event during COVID-19, n (%)
Mechanical ventilation during COVID-19, n (%)
Death due to COVID-19, n (%)

53 (46e65)
70
16
9
31.5

(73.7)
(16.8)
(9.5)
(27.4e36.3)

Testosterone
replacement (n ¼ 32)
52 (45e66)
22
6
4
32.7

(68.8)
(18.8)
(12.5)
(27.9e38.0)

Matched controls
(n ¼ 63)
54 (47e64)
48
10
5
31.2

(76.2)
(15.9)
(7.9)
(27.1e35.8)

16
39
10
16
14

(16.8)
(41.1)
(10.5)
(16.8)
(14.7)

5
13
4
4
6

(15.6)
(40.6)
(12.5)
(12.5)
(18.8)

11
26
6
12
8

(17.5)
(41.3)
(9.5)
(19.1)
(12.7)

20
31
21
32
56
17
44
60
20
12
15
11

(21.1)
(32.6)
(22.1)
(33.7)
(59.0)
(17.9)
(46.3)
(63.2)
(21.1)
(12.6)
(15.8)
(11.6)

4
12
6
13
21
8
15
20
4
4
3
3

(12.5)
(37.5)
(18.8)
(40.6)
(65.6)
(25.0)
(46.9)
(62.5)
(12.5)
(12.5)
(9.4)
(9.4)

16
19
15
19
35
9
29
40
16
8
12
8

(25.4)
(30.2)
(23.8)
(30.2)
(55.6)
(14.3)
(46.0)
(63.5)
(25.4)
(12.7)
(19.1)
(12.7)

P value
.3

.7
.2

.9
.1
.5
.6
.3
.3
.2
.9
.9
.1
.7
.2
.7

BMI ¼ body mass index; COPD ¼ chronic obstructive pulmonary disease; ICU ¼ intensive care unit.

disease, cardiovascular disease, chronic kidney disease, and
immunosuppression status were collected. COVID-19erelated
endpoints were extracted including hospital admission, intensive
care unit (ICU) admission, mechanical ventilator utilization,
thromboembolic events, and death. Chi-square and KruskalWallis tests examined differences in categorical and continuous
variables, respectively. Logistic regression analysis tested the
relationship between TRT status and the study endpoints.
Covariates consisted of age, race, BMI, ZIP code, smoking status,
and comorbidity (as a cumulative number).

RESULTS
A total of 3,697 men diagnosed with COVID-19 were identiﬁed of which 38 were on TRT. 6 men in the TRT group and
13 men in the control group had incomplete data and were
excluded resulting in inclusion of 32 men in the TRT and 63
men in the control groups. Among men on TRT, 32 were
diagnosed with hypogonadism (2 hypergonadotropic, 7 hypogonadotropic, and 23 mixed). 23 men received intramuscular
testosterone cypionate injections while 9 were on transdermal
testosterone gel. Descriptive characteristics are reported in

Table 2. Multivariable logistic regression analysis testing the impact of testosterone replacement therapy on the clinical outcomes of men
with new coronavirus infection 2019 (COVID-19)
Endpoints

Odds ratio

95% Conﬁdence interval

Hosmer and Lemeshow
goodness of ﬁt

Hospital admission
Intensive care unit admission
Mechanical ventilator utilization
Thromboembolic event
Death

0.997
0.323
0.465
0.540
1.713

0.34e2.86
0.07e1.34
0.10e2.08
0.09e3.13
0.13e21.24

0.750
0.981
0.650
0.895
0.611

All multivariable analyses were adjusted to age, race, body mass index, smoking status, comorbidity (as a cumulative number), and ZIP code. The control
group was set as the reference category.
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Table 1. Median age (IQR) was 53 years (46e65), and BMI
(IQR) was 31 (27.4e36.3). Mean testosterone (IQR) level for
those on TRT was 397 (212.5e454.75) ng/dl. Patients on TRT
had higher rates of hypertension (65.6% vs 55.5%), cardiovascular disease (37.5% vs 30.1%), diabetes mellitus (40.6% vs
30.1%), and immunosuppression (25% vs 14.2%) and a lower
rate of chronic obstructive pulmonary disease than controls
(12.5% vs 25.4%), none of which were statistically signiﬁcant
(all P  .1). When focusing on endpoints, patients on TRT had
similar rates of hospitalization (62.5% vs 63.4%, P ¼ .9),
thromboembolic events (12.5% vs 12.7%, P ¼ .7), and death
(9.3% vs 12.7%, P ¼ .7) as their counterparts not on TRT.
Patients on TRT had lower rates of ICU admission (12.5% vs
25.4%, P ¼ .1) and mechanical ventilator utilization (9.3% vs
19.0%, P ¼ .2) than patients not on TRT, but none were statistically signiﬁcant. TRT was not an independent predictor of
any of the examined endpoints on multivariable analysis
(Table 2).

DISCUSSION
To our knowledge, this is the ﬁrst study looking at outcomes
of men on TRT who developed COVID-19. In our cohort, the
thromboembolic and death rates were similar in both groups.
Despite having a higher rate of baseline comorbidities, there were
lower rates of ICU admission and mechanical ventilator utilization that were observed in the TRT group, although not statistically signiﬁcant.
Androgens are needed for the SARS-CoV-2 to infect cells
via activation of TMPRSS2 which serves to prime the spike
protein needed for entry into cells.3 Based on this, clinical
trials have begun with antiandrogens and TMPRSS2 inhibitors
as prophylactic agents. There may also be a role for 5-a
reductase inhibitors and luteinizing hormoneereleasing hormone agonists/antagonists in this setting.6 In fact, it was found
that even though patients diagnosed with cancer have an
increased risk of contracting COVID-19, men on androgen
deprivation therapy for prostate cancer had a lower risk of
developing an infection.7
Once an infection occurs, testosterone may serve a protective
role by decreasing the risk of a cytokine storm.2 A recent report
observed lower levels of testosterone in men who were admitted
to the ICU with SARS-CoV-2 infections.8 It is unknown
whether these men had a low testosterone level at baseline or if
they developed a low testosterone level in response to the
infection. There is evidence to suggest that most men admitted
to acute care units have a transient suppression of testosterone to
a level below the normal range.9 A decreased testosterone level is
associated with an increase in proinﬂammatory markers such as
IL-1b, IL-6, and TNF-a.10 Testosterone may facilitate cell
infection with the SARS-CoV-2 but also be protective of worse
clinical outcomes during active infections. A study measuring

J Sex Med 2021;18:215e218

testosterone levels of men at baseline and at various times during
COVID-19 may help further delineate this relationship.
Androgens appear to play an important role in COVID-19,
but the overall clinical picture is a much more complex interplay between exposure risks, age, comorbidities, genetic predisposition, and socioeconomic status. A combination of these
factors may be responsible for the differences in disease severity
between men and women. Limitations of this study include a
small sample size, which limits the statistical power of the study.
Other limitations are unknown testosterone levels in men of the
control cohort and the retrospective nature of this study with the
potential for residual bias caused by unobserved confounders,
even after propensity score matching. In conclusion, our study
failed to demonstrate a statistically signiﬁcant difference in
COVID-19 outcomes among men treated with TRT and those
not on TRT. Future studies are needed to help further guide
clinicians on the optimal management of hypogonadism with
TRT in the era of COVID-19.
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